AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials

Core Insights - Tozorakimab achieved its primary goal in two late-stage clinical trials by effectively reducing the rate of symptom worsening in patients [1] Company Summary - The company reported successful outcomes from two late-stage clinical trials involving Tozorakimab, indicating its potential effectiveness in treating patients [1]